![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Fispemifene.svg/640px-Fispemifene.svg.png&w=640&q=50)
Fispemifene
Chemical compound / From Wikipedia, the free encyclopedia
Fispemifene (INN, USAN) (developmental code name HM-101) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was developed for the treatment of male hypogonadism but was abandoned and never marketed.[1][2][3] It reached phase II clinical trials for this indication before development was terminated in March 2016.[1] The drug failed to achieve statistical significance on key effectiveness endpoints in clinical trials and was discontinued by its developer for strategic reasons.[1]
Quick Facts Clinical data, Other names ...
![]() | |
Clinical data | |
---|---|
Other names | HM-101 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C26H27ClO3 |
Molar mass | 422.95 g·mol−1 |
3D model (JSmol) | |
| |
|
Close